Teva Pharmaceutical Industries (TEVA) Total Current Liabilities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Total Current Liabilities for 18 consecutive years, with $13.5 billion the latest figure, recorded in Q1 2026.

• Quarterly Total Current Liabilities rose 21.29% year-over-year to $13.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.5 billion (up 21.29% YoY) and the FY2025 annual result came in at $13.5 billion, up 5.16% from the prior year.
• Total Current Liabilities advanced to $13.5 billion in Q1 2026 per TEVA's latest filing, from $13.5 billion in the prior quarter.
• Over the last five years, Total Current Liabilities for TEVA reached as high as $13.8 billion in Q3 2024 and fell as low as $10.4 billion in Q1 2023.
• A 5-year average of $12.1 billion and a median of $11.8 billion in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities jumped 32.48% — and 2025, when it declined 19.11%.
• Year by year, Total Current Liabilities stood at $11.5 billion in 2022, then grew by 6.78% to $12.2 billion in 2023, then increased by 4.48% to $12.8 billion in 2024, then advanced by 5.16% to $13.5 billion in 2025, then increased by 0.56% to $13.5 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $13.5 billion, $13.5 billion, and $11.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.